Orasure Technologies OSUR
Orasure Technologies Q2 FY26: revenue $30.6M, down 2%; diluted EPS $0.09
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001116463-26-000052
Key figures from this report
These are the numbers Orasure Technologies reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$30.6M−2% from $31.2M in Q2 FY2510-Q income statement, on EDGAR
- Net income$6.2MAgainst −$19.7M in Q2 FY2510-Q income statement, on EDGAR
- Diluted EPS$0.09Against −$0.26 in Q2 FY2510-Q income statement, on EDGAR
- Cash and cash equivalents$160.6M−32% from $234.6M in Q2 FY2510-Q balance sheet, on EDGAR
- Cash from operations−$9.9MAgainst −$10.2M in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Same SIC code (3841) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.
- Tactile Systems Technology TCMD public float $223M, Jun 30, 2025
- Cerus CERS public float $230M, Jun 30, 2025
- SANUWAVE Health SNWV public float $233M, Jun 30, 2025
- Bioventus BVS public float $264M, Jun 28, 2025
- Treace Medical Concepts TMCI public float $266M, Jun 30, 2025